IL‐24 Induces Cell Dormancy and Oxaliplatin Resistance in Colon Cancer Cells by Activating NF‐κB Pathway
Molecular Carcinogenesis · 2026-09 · 65 (9) · 1126-1139
DOI: 10.1002/mc.70147 ↗At a glance
Journal article in Molecular Carcinogenesis, published online on 2026-07-16. Written by Yanyan Hu and 4 co-authors. Institution: Clinical Laboratory, Sanmen People's Hospital, Sanmen, China. Major MEDLINE topics: Oxaliplatin, Colonic Neoplasms, NF-kappa B, Drug Resistance, Neoplasm. 47 references. The full text is freely available in PubMed Central. Funded by: National Natural Science Foundation of China, Zhejiang Medical and Health Science and Technology Plan, Zhejiang Provincial County Level Advantageous Disciplines of Traditional Chinese Medicine Construction Plan.
Abstract (original language)
Oxaliplatin‐based chemotherapy is a principal treatment for colon cancer, but drug resistance hinders its efficacy. Cancer cell dormancy is reportedly a crucial driver of chemoresistance. IL‐24 functions vitally in tumor chemoresistance, yet its role in colon cancer dormancy and oxaliplatin resistance remains unexplored.IL‐24 expression was assessed in colon cancer tissues and cells via RT‐qPCR, western blotting, or immunohistochemistry. The functions of IL‐24 in colon cancer cell proliferation, apoptosis, dormancy, and oxaliplatin resistance were evaluated by CCK‐8, flow cytometry, and western blotting. The downstream mechanism of IL‐24 was predicted using RNA sequencing and bioinformatics analyses and verified in vitro. A tumor xenograft mouse model was built to further verify the role of IL‐24 in colon cancer. IL‐24 was overexpressed in oxaliplatin‐resistant colon cancer tissues and cells. Furthermore, IL‐24 treatment reversed the anti‐proliferative and pro‐apoptotic effects of oxaliplatin on colon cancer cells. Regarding cell dormancy, IL‐24 treatment triggered G0/G1 cell cycle arrest and upregulated dormancy markers (CDKN1A, CDKN1B, TGFB2, and MSK1). Bioinformatics analyses revealed that IL‐24 might function in colon cancer mainly through NF‐κB pathway, and IL‐24 activated the NF‐κB axis in tumor cells. Importantly, treatment with NF‐κB inhibitor reversed IL‐24‐induced colon cancer cell dormancy and oxaliplatin resistance. In vivo, IL‐24 treatment abolished the anti‐tumor effects of oxaliplatin, promoted cell dormancy, and activated NF‐κB signaling in tumor tissues. IL‐24 induces colon cancer cell dormancy and oxaliplatin resistance by activating NF‐κB signaling. The IL‐24/NF‐κB axis may serve as a likely target to alleviate oxaliplatin resistance in colon cancer.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Clinical Laboratory, Sanmen People's Hospital, Sanmen, China.
- Office of Drug Clinical Trial Institutions, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, China.
- Central Laboratory, The Affiliated Xuzhou Municipal Hospital, Xuzhou Medical University, Xuzhou, China.
- Central Laboratory, Sanmen People's Hospital, Sanmen, China.
ORCID profiles: Chaoju Gong
Funding
- National Natural Science Foundation of China
- Zhejiang Medical and Health Science and Technology Plan
- Zhejiang Provincial County Level Advantageous Disciplines of Traditional Chinese Medicine Construction Plan
Cite
APA
Hu, Y., Li, S., Zhu, M., Gong, C., & Fang, Z. (2026). IL‐24 Induces Cell Dormancy and Oxaliplatin Resistance in Colon Cancer Cells by Activating NF‐κB Pathway. Molecular Carcinogenesis, 65(9), 1126-1139. https://doi.org/10.1002/mc.70147
Vancouver
Hu Y, Li S, Zhu M, Gong C, Fang Z. IL‐24 Induces Cell Dormancy and Oxaliplatin Resistance in Colon Cancer Cells by Activating NF‐κB Pathway. Molecular Carcinogenesis. 2026;65(9):1126-1139. doi:10.1002/mc.70147
BibTeX
@article{Hu2026,
author = {Hu, Yanyan and Li, Shengying and Zhu, Minjing and Gong, Chaoju and Fang, Zejun},
title = {IL‐24 Induces Cell Dormancy and Oxaliplatin Resistance in Colon Cancer Cells by Activating NF‐κB Pathway},
journal = {Molecular Carcinogenesis},
year = {2026},
volume = {65},
number = {9},
pages = {1126--1139},
doi = {10.1002/mc.70147}
}
EUVIMED